Novartis Aktie
WKN: 904278 / ISIN: CH0012005267
28.08.2024 07:14:45
|
Press Release: Novartis twice-yearly* Leqvio(R) -2-
References
1. Data on file. Study NCT05763875. Novartis Pharmaceuticals Corp; 2024.
2. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the
Primary Prevention of Cardiovascular Disease. Journal of the American
College of Cardiology. 2019;74(10):e177-e232.
doi:https://doi.org/10.1016/j.jacc.2019.03.010
3. ClinicalTrials.gov. NCT05763875. Accessed August 21, 2024.
https://clinicaltrials.gov/study/NCT05763875
4. Leqvio. Summary of Product Characteristics. Novartis.
5. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp.
6. National Medical Products Administration. Drug approval document delivery
information. Published August 24, 2023. Accessed March 12, 2024.
https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20230824155809182.html
7. Pharmaceutical and Medicinal Devices Agency Japan. New drugs approved in
FY 2023 document. Accessed August 21, 2024.
https://www.pmda.go.jp/files/000269225.pdf
8. American Heart Association. More than half of U.S. adults don't know
heart disease is leading cause of death, despite 100-year reign.
Published January 24, 2024. Accessed August 21, 2024.
https://newsroom.heart.org/news/more-than-half-of-u-s-adults-dont-know-heart-disease-is-leading-cause-of-death-despite-100-year-reign
9. World Heart Federation. World Heart Report. Published May 20, 2023.
Accessed August 21, 2024.
https://world-heart-federation.org/wp-content/uploads/World-Heart-Report-2023.pdf
10. World Health Organization. Cardiovascular diseases (CVDs). Published June
11, 2021. Accessed August 21, 2024.
https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-
(cvds)
11. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke
statistics--2012 update: a report from the American Heart Association.
Circulation. 2012;125(1):e2-e220.
12. Kim H, Kim S, Han S, et al. Prevalence and incidence of atherosclerotic
cardiovascular disease and its risk factors in Korea: a nationwide
population-based study. BMC Public Health. 2019;19(1):1112.
13. Grundy SM, Stone NJ, Bailey AL, et al. 2018
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the
management of blood cholesterol: a report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines. Circulation. 2019;139:e1082--e1143.
14. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from
plaques to genes to statins. Cell. 2015;161(1):161-172.
15. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on
cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol.
2018;72(10):1141-1156.
# # #
Novartis Media Relations
E-mail:media.relations@novartis.com
Central North America
Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414
Anna Schäfers +41 79 801 7267
Switzerland
Satoshi Sugimoto +41 79 619 2035
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail:investor.relations@novartis.com
Central North America
Isabella Zinck +41 61 324 7188 Sloan Simpson +1 862 345 4440
Nicole Zinsli-Somm +41 61 324 3809 Jonathan Graham +1 201 602 9921
Imke Kappes +41 61 324 8269 Parag Mahanti +1 973 876 4912
(END) Dow Jones Newswires
August 28, 2024 01:15 ET (05:15 GMT)

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novartis AGmehr Nachrichten
01.04.25 |
Aufschläge in Zürich: SMI mittags auf grünem Terrain (finanzen.at) | |
01.04.25 |
SPI-Handel aktuell: SPI beginnt Dienstagshandel mit Gewinnen (finanzen.at) | |
01.04.25 |
Freundlicher Handel: Börsianer lassen SMI zum Start steigen (finanzen.at) | |
01.04.25 |
SLI aktuell: Börsianer lassen SLI zum Start des Dienstagshandels steigen (finanzen.at) | |
01.04.25 |
Gewinne in Europa: Zum Start Pluszeichen im STOXX 50 (finanzen.at) | |
31.03.25 |
Verluste in Zürich: SMI verbucht letztendlich Verluste (finanzen.at) | |
31.03.25 |
Schwacher Handel: SMI liegt nachmittags im Minus (finanzen.at) | |
31.03.25 |
Schwache Performance in Zürich: SLI verliert mittags (finanzen.at) |
Analysen zu Novartis AGmehr Analysen
06.03.25 | Novartis Buy | Deutsche Bank AG | |
25.02.25 | Novartis Neutral | JP Morgan Chase & Co. | |
20.02.25 | Novartis Outperform | Bernstein Research | |
18.02.25 | Novartis Buy | Deutsche Bank AG | |
13.02.25 | Novartis Neutral | UBS AG |
Aktien in diesem Artikel
Novartis AG | 80,10 | -0,27% |
|
Novartis AG (Spons. ADRS) | 101,00 | -1,46% |
|